Physician profile
Christopher Cross
NPI 1013170596
$12,216.50
in general payments reported to CMS, 2019-2025
30 companies · $1,428 in 2025
The $1,428 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,044 · 2020: $994 · 2021: $1,587 · 2022: $2,671 · 2023: $1,809 · 2024: $1,683 · 2025: $1,428.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,709 · Travel and Lodging: $164 · Education: $47.06.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,709.40 |
| Travel and Lodging | $164.29 |
| Education | $47.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,920.27 | 2019-2025 | Rinvoq, Skyrizi, Mavyret |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,668.36 | 2019-2025 | Trulance, Xifaxan, Plenvu |
| Gilead Sciences, INC. | $1,161.53 | 2019-2025 | |
| Janssen Biotech, INC. | $973.09 | 2019-2025 | Tremfya, Stelara, Remicade |
| Olympus Corporation of The Americas | $949.07 | 2022-2023 | Visiglide, Hanarostent Lowaxtm Duodenum/Pylorus(Nnn), Disposable Distal Attachment |
| Takeda Pharmaceuticals U.S.A., INC. | $888.94 | 2019-2025 | Entyvio, Eohilia |
| Pfizer INC. | $779.13 | 2019-2025 | |
| Braintree Laboratories, INC. | $258.32 | 2019-2022 | |
| Genzyme Corporation | $245.12 | 2023-2025 | |
| Allergan, INC. | $194.86 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $174.38 | 2023-2025 | Dupixent |
| Ironwood Pharmaceuticals, INC | $120.65 | 2019-2024 | Linzess |
| Intercept Pharmaceuticals, INC. | $112.32 | 2019-2021 | |
| Celgene Corporation | $110.00 | 2021-2023 | Zeposia |
| Ucb, INC. | $104.56 | 2019-2020 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $93.52 | 2020-2024 | Dificid |
| Ardelyx, INC. | $73.09 | 2022-2025 | Ibsrela |
| Celltrion USA INC. | $56.81 | 2024-2025 | Zymfentra, Vegzelma |
| Nestle Healthcare Nutrition INC. | $53.47 | 2021-2023 | |
| Madrigal Pharmaceuticals | $52.10 | 2024-2025 | Rezdiffra, Resmetirom |
| Ipsen Biopharmaceuticals, INC | $38.91 | 2024-2025 | Iqirvo |
| Qol Medical, LLC | $33.39 | 2023-2024 | Sucraid, Sucraid |
| Medtronic, INC. | $28.72 | 2023 | Interstim |
| Redhill Biopharma INC. | $27.87 | 2021 | |
| Phathom Pharmaceuticals, INC. | $25.85 | 2024-2025 | Voquezna |
| Mauna Kea Technologies, INC. | $18.35 | 2019 | |
| Novo Nordisk INC | $14.71 | 2025 | Wegovy |
| Sandoz INC. | $14.35 | 2023 | Hyrimoz |
| Cook Medical LLC | $12.71 | 2019 | |
| Ferring Pharmaceuticals INC. | $12.05 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Cross listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.